US 20150297652A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2015/0297652 A1 Balaraman (43) Pub. Date: Oct. 22, 2015

(54) COMPOSITIONS AND METHODS FOR A61R 36/79 (2006.01) THEIR DERMATOLOGICAL USE A61 K. 36/74 (2006.01) A61 K. 36/539 (2006.01) (71) Applicant: VITA NATURALE, LLC, St. Louis, A61 K. 36/53 (2006.01) MO (US) A61 K. 36/882 (2006.01) A61 K. 36/282 (2006.01) (72) Inventor: Brundha Balaraman, St. Louis, MO A61 K. 36/48 (2006.01) (US) A61 K. 36/23 (2006.01) - (52) U.S. CI. (21) Appl. No.: 14/646,049 CPC ...... A61K 36/074 (2013.01); A61K 36/48 (2013.01); A61K 36/489 (2013.01); A61 K (22) PCT Filed: Nov. 19, 2013 36/185 (2013.01); A61K 36/58 (2013.01); - A61K 36/23 (2013.01); A61K 36/74 (2013.01); (86) PCT No.: PCT/US13/70779 A61K 36/539 (2013.01); A61K 36/53 § 371 (c)(1), (2013.01); A61K 36/882 (2013.01); A61 K (2) Date: May 20, 2015 36/282 (2013.01); A61K 36/79 (2013.01) Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 61/728,386, filed on Nov. Compositions containing Albizia lebbeck and/or Sophora fla 20, 2012. vescens and/or Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. Emblica officinalis) and/or Publication Classification and/or Centella asiatica and/or Ganoderma and/or Rubia cordifolia and/or Scutellaria baicalensis and/or (51) Int. Cl. membranaceus and/or Ocimum tenuiflorum (syn. Ocimum A6 IK 36/074 (2006.01) sanctum) and/or Acorns and/or Artemisia and/or Rheum and/ A6 IK 36/489 (2006.01) or Schisandra and/or Ophiopogon japonicas and their use in A6 IK 36/185 (2006.01) preventing, treating, alleviating symptoms and/or mitigating A61K 36/58 (2006.01) skin disorders and/or disease are provided. US 2015/0297652 A1 Oct. 22, 2015

COMPOSITIONS AND METHODS FOR of the pancreas occurring after an acute attack (Sidhu et al. THEIR DERMATOLOGICAL USE Journal of Medicinal Food 2011 14 (1–2): 147-155). Prepa rations of leaves, bark and/or fruit have also shown potential [0001] This patent application claims the benefit of priority efficacy against inflammation, cancer, age-related renal dis from U.S. Provisional Application Ser. No. 61/728,386, filed ease and diabetes in disease models (Ganju et al. Biomed Nov. 20, 2012, the teachings of which are herein incorpo Pharmacother 2003 57 (7): 296-300; Yokozawa et al. JAgric ratred by reference in their entirety. Food Chem. 2007 55(19): 7744-52; Rao et al. J Med Food FIELD OF THE INVENTION 2005 8 (3): 362-8; and Qureshi et al. Pakistan Journal of Nutrition 2009 8 (2): 125-128) and a pilot study in humans [0002] The present invention relates to compositions con showed a reduction of blood cholesterol levels in both normal taining Albizia lebbeck and/or Sophora flavescens and/or and hypercholesterolemic men upon treatment with a berry Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. extract (Jacob et al. Eur J Clin Nutr 1988 42 (11): 939-44). Emblica officinalis) and/or Azadirachta indica and/or Cen [0007] Azadirachta indica, also referred to as NEEM, has tella asiatica and/or Ganoderma and/or Rubia cordifolia and/ been disclosed to have anti-bacterial, anti-parasitic, anti-fun or Scutellaria baicalensis and/or Astragalus membranaceus gal, anti-protozoal and anti-viral properties. NEEM, when and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or applied in the form of a powder or oil has been disclosed to Acorus and/or Artemisia and/or Rheum and/or Schisandra have exceptional results on external cuts or wounds and to to and/or Ophiopogon japonicus. The present invention also be very effective in relieving skin ailments such as eczema, relates to use of these compositions in preventing, treating, acne, skin allergy, rashes, itch, ringworms, etc. NEEM water alleviating symptoms and/or mitigating skin disorders and/or is also described as being very effective when used to treat disease. burn injuries. In addition, NEEM oil is suggested to prevent hair from graying and to be effective in treating dandruff, lice BACKGROUND OF THE INVENTION and hair loss. NEEM oil has also been suggested for use in [0003] Albizia lebbeck is a species of Albizia, fast-growing massaging muscle aches and joints to releive pain from con subtropical and tropical trees and shrubs, native to Indoma ditions such as rheumatoid arthritis, gout, osteoarthritis and laya, New Guinea and Northern Australia. Lebbeck is an lower back pain. Ingesting NEEM is suggested to be benefi astringent and has been used by some cultures in the treatment cial in restoring taste, curing constipation and relieving indi or alleviation of boils, cough, eye disordors, flu symptoms, gestion. It also eliminates the problem of acidity. See gingivitis, lung problems and pectoral problems. It has been soultemplemet with the extension .org/profiles/blogs/health suggested for use as an oral tonic in the treatment of abdomi benefits-of-azadirachta of the world wide web. nal tumors. (See, for example, Duke, Jame A., Dr. Duke’s [0008] Centella is used as a leafy green in various cuisines Phytochemical and Ethnobotanical Databases—Albizia leb and is considered quite nutritious. However, while Centella beck 2008). The bark is used medicinally to treat inflamma asiatica has been promoted for its health benefits, available tion (Lowry et al. (1994): 2.5 Albizia lebbeck—a Promising scientific evidence has not supported claims of its effective Forage Tree for Semiarid Regions. In: Gutteridge, Ross C. ness for treating cancer or any other diseases in humans and Shelton H. Mac (eds.):Forage Tree Legumes in Tropical (“Gotu Kola” American Cancer Society. 28 Nov. 2011). Agriculture. CAB Intemational). [0009] Ganoderma is a genus of polypore mushrooms [0004] Sophora flavescens is a species of in the genus which grow on wood, and include about 80 species. Collec Sophora. About fifteen species in this genus have been used in tively, the Ganoderma species are being investigated for a traditional Chinese medicines. Common suggested uses variety of potential therapeutic benefits including anticancer include treatment of viral hepatitis, enteritis, cancer, viral effects, immunoregulatory effects, antioxidant activities, myocarditis, gastrointestinal hemorrhage and skin diseases liver-protecting effects, hypoglycemic effects, antibacterial such as vaginitis, psoriasis and eczema. effects, antiviral effects, antifungal effects and reducing [0005] Hibiscus rosa-sinensis, also known as rose mallow, blood cholesterol (Yuen, J W and Gohel, M. D. Nutr Cancer Chinese hibiscus, China rose and shoe flower, is a species of 2005 53 (1): 11-7; Xu et al. American Journal of Chinese in the family Malvaceae. Hibiscus rosa-sin Medicine 2011 39 (1): 15-27; Sliva D. Mini Reviews in ensis has also been used traditionally in Chinese medicines. Medicinal Chemistry 2004 4 (8): 873-9; and Sanodiya et al. An extract from the flowers of Hibiscus rosa-simensis has Current Pharmaceutical Biotechnology 2009 10(8): 717-42). been shown to function as an anti-solar agent by absorbing ultraviolet radiation (Nevade etal. 2011. Linn. Research Jour [0010) Rubia cordifolia, also known as Common Madder nal of Pharmacy and Technology 4(3): 472-473). or Indian Madder, is a species of flowering plant in the coffee [0006] Phyllanthus emblica (syn. Emblica officinalis), is a family, Rubiaceae. It has been cultivated for a red pigment deciduous tree of the family Phyllanthaceae. Preliminary derived from roots and has been described to have anti-in research has shown in vitro antiviral and antimicrobial prop flammatory properties and induce urolithiasis in cellular and erties of its berries (Saeed, S. and Tariq, P, Pak J Pharm Sci animal models (Joshan et al. Biomedical and Pharmacology 2007 2001): 32-5). There is also preliminary evidence in vitro Journal 2010 3:1 123-128; and Divakar et al. Food and that its berry extracts induce apoptosis and modify gene Chemical Toxicology 2010 48:4 1013-1018). expression in osteoclasts involved in rheumatoid arthritis and [0011] Scutellaria baicalensis and Astragalus propinquus osteoporosis (Penolazzi et al. BMC Complementary and are species of flowering in the Lamiaceae family and 2008 8: 59) and may prove to have family , respectively. Both are included in the 50 activity against some cancers (Ngamkitidechakul et al. Phy fundamental herbs used in traditional Chinese medicine. A. totherapy Research 2010 24 (9): 1405-1413). A recent study propinquus has been asserted to be a tonic that can improve in rats showed E. officinalis to reduce severity of acute pan the functioning of the lungs, adrenal glands and the gas creatitis and to promote spontaneous repair and regeneration trointestinal tract, increase metabolism and sweating, pro US 2015/0297652 A1 Oct. 22, 2015

mote healing, and reduce fatigue (Balch, P. 2006 Prescription Ocimum sanctum) and/or Acorus and/or Artemisia and/or for Nutritional Healing (4th ed.) Avery Penguin Putnam). Rheum and/or Schisandra and/or Ophiopogon japonicus for [0012] Ocimum tenuiflorum, also known as Ocimum sanc mulated in, for example, ointments, creams, lotions, solu tum, Holy basil, or tulasi, is an aromatic plant in the family tions, pastes (e.g. facial mask), gels, emulsions, sprays, aero Lamiaceae. In vitro and animal studies have indicated some sols, oils, patches, toothpastes, mouthwashes, deodorants, potential pharmacological properties of Ocimum tenuiflorum soaps, body and/or face washes, sponges, foams, semi-solids, or its extracts as painkillers, antihyperlipidemics, cardiopro cosmetics (e.g. solid, semisolid, liquid, or powder founda tectants, anti-cancer agents and mitigants of the effects of tion, eye shadow, lip balm), application sticks, sunscreens, radiation exposure, and antibacterial agents (Prakash, P. and depots, suppositories, sustained-release formulations (a Gupta, N. Indian Journal of Physiology and Pharmacology unique variation of this concept presented herein involves tea 2005 49 (2): 125-131; Suanarunsawat et al. bag-like carriers made of plastic, silk, nylon, Soilon or paper), [0013] Journal of Basic and Clinical Physiology and Phar troches, tablets, pills, capsules, syrups, elixirs, suspensions, macology 2010 21 (4): 387-400; Baliga et al. Nutrition and wafers, foods (e.g. chewing gum, mints, etc.), beverages or cancer 2013 65 Suppl 1: 26-35; and Golshahi et al. Clinical other formulations which accomplish direct contact between Biochemistry. Conference: 12th Iranian Congress of Bio the composition of the present invention and a cutaneous or chemistry, ICB and 4th International Congress of Biochem mucosal surface or lesion. istry and Molecular Biology 2011 44 (13 SUPPL. 1); S352). [0020] Another aspect of the present invention relates to a [0014] Acorus is a genus of monocot flowering plants and method of preventing, mitigating, and/or treating skin disor Artemisia is a genus of plants including the sagebrush and ders and/or diseases by administering to a subject having or wormwood. suspected of having a skin disorder and/or disease a compo [0015] Rheumis a genus of about 60 perennial plants in the sition comprising Albizia lebbeck and/or Sophora flavescens family Polygonaceae. Many rheum species have food and and/or Hibiscus rosa sinensis and/or Phyllanthus emblica medicinal uses dating back as far as 2000 years ago. (syn. Emblica officinalis) and/or Azadirachta indica and/or [0016] Oral administration of schisandra has been investi Centella asiatica and/or Ganoderma and/or Rubia cordifolia gated for a number of conditions including hepatitis; improv and/or Scutellaria baicalensis and/or Astragalus membrana ing mental and physical performance; increasing resistance to ceus and/or Ocimum tenuiflorum (syn. Ocimum sanctum) disease and stress; preventing aging; normalizing blood sugar and/or Acorus and/or Artemisia and/or Rheum and/or and blood pressure; stimulating the immune system and Schisandra and/or Ophiopogon japonicus. speeding recovery after surgery; treating high cholesterol, coughs, asthma, sleep problems, nerve pain, premenstrual DETAILED DESCRIPTION OF THE INVENTION syndrome (PMS), chronic diarrhea, dysentery, night sweats, [0021] The present invention relates to compositions com spontaneous sweating, involuntary discharge of semen, thirst, prising Albizia lebbeck and/or Sophora flavescens and/or erectile dysfunction (ED), physical exhaustion, excessive uri Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. nation, depression, irritability, and memory loss; improving Emblica officinalis) and/or Azadirachta indica and/or Cen vision; protecting against radiation, preventing motion sick tella asiatica and/or Ganoderma and/or Rubia cordifolia and/ ness; preventing infection; boosting energy at the cellular or Scutellaria baicalensis and/or Astragalus membranaceus level; counteracting the effects of sugar; and improving the and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or health of the adrenal glands. Acorus and/or Artemisia and/or Rheum and/or Schisandra [0017| Ophiopogon japonicus, also known as Mondo and/or Ophiopogon japonicus. grass, Fountain plant and monkey grass, is also used in tradi [0022] In one embodiment, the composition of the present tional Chinese medicine. According to the Chinese invention comprises Albizia lebbeck and one or more agents Medicine Materia Medica, the herb is sweet, slightly bitter selected from the group consisting of Sophora flavescens and slightly cold, enters the heart, lung and stomach channels and/or Hibiscus rosa sinensis and/or Phyllanthus emblica and nourishes the yin of the stomach, spleen, heart and lungs (syn. Emblica officinalis) and/or Azadirachta indica and/or and clears heat and quiets irritability. Centella asiatica and/or Ganoderma and/or Rubia cordifolia and/or Scutellaria baicalensis and/or Ocimum tenuiflorum SUMMARY OF THE INVENTION (syn. Ocimum sanctum) and/or Acorus and/or Artemisia and/ [0018] An aspect of the present invention relates to a com or Rheum and/or Schisandra and/or Ophiopogon japonicus. position comprising Albizia lebbeck and/or Sophora flave [0023] In another embodiment, the composition of the scens and/or Hibiscus rosa sinensis and/or Phyllanthus present invention comprises Sophora flavescens and one or emblica (syn. Emblica officinalis) and/or Azadirachta indica more agents selected from the group consisting of Albizia and/or Centella asiatica and/or Ganoderma and/or Rubia lebbeck and/or Hibiscus rosa sinensis and/or Phyllanthus cordifolia and/or Scutellaria baicalensis and/or Astragalus emblica (syn. Emblica officinalis) and/or Azadirachta indica membranaceus and/or Ocimum tenuiflorum (syn. Ocimum and/or Centella asiatica and/or Ganoderma and/or Rubia sanctum) and/or Acorus and/or Artemisia and/or Rheum and/ cordifolia and/or Scutellaria baicalensis and/or Ocimum or Schisandra and/or Ophiopogon japonicus. tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or [0019] Another aspect of the present invention relates to a Artemisia and/or Rheum and/or Schisandra and/or Ophio formulation for topical intralesional or oral administration pogon japonicus. comprising a composition comprising Albizia lebbeck and/or [0024] In another embodiment, the composition comprises Sophora flavescens and/or Hibiscus rosa sinensis and/or Hibiscus rosa sinensis and one or more agents selected from Phyllanthus emblica (syn. Emblica officinalis) and/or Aza the group consisting of Albizia lebbeck and/or Sophora fla dirachta indica and/or Centella asiatica and/or Ganoderma vescens and/or Phyllanthus emblica (syn. Emblica officinalis) and/or Rubia cordifolia and/or Scutellaria baicalensis and/or and/or Azadirachta indica and/or Centella asiatica and/or Astragalus membranaceus and/or Ocimum tenuiflorum (syn. Ganoderma and/or Rubia cordifolia and/or Scutellaria US 2015/0297652 A1 Oct. 22, 2015

baicalensis and/or Ocimum tenuiflorum (syn. Ocimum sanc Albizia lebbeck and/or Sophora flavescens and/or Hibiscus tum) and/or Acorus and/or Artemisia and/or Rheum and/or rosa sinensis and/or Phyllanthus emblica (syn. Emblica offi Schisandra and/or Ophiopogon japonicus. cinalis) and/or Azadirachta indica and/or Centella asiatica [0025] In another embodiment, the composition comprises and/or Ganoderma and/or Rubia cordifolia and/or Scutel Phyllanthus emblica (syn. Emblica officinalis) and one or laria baicalensis and/or Ocimum tenuiflorum (syn. Ocimum more agents selected from the group consisting of Albizia sanctum) and/or Acorus and/or Artemisia and/or Rheum and/ lebbeck and/or Sophora flavescens and/or Hibiscus rosa sin or Schisandra and/or Ophiopogon japonicus. ensis and/or Azadirachta indica and/or Centella asiatica and/ [0032] In yet another embodiment, the composition of the or Ganoderma and/or Rubia cordifolia and/or Scutellaria present invention comprises Ocimum tenuiflorum (syn. Oci baicalensis and/or Ocimum tenuiflorum (syn. Ocimum sanc mum sanctum) and one or more agents selected from the tum) and/or Acorus and/or Artemisia and/or Rheum and/or group consisting of Albizia lebbeck and/or Sophora flave Schisandra and/or Ophiopogon japonicus. scens and/or Hibiscus rosa sinensis and/or Phyllanthus [0026] In yet another embodiment, the composition of the emblica (syn. Emblica officinalis) and/or Azadirachta indica present invention comprises Azadirachta indica and one or and/or Centella asiatica and/or Ganoderma and/or Rubia more agents selected from the group consisting of Albizia cordifolia and/or Scutellaria baicalensis and/or Acorus and/ lebbeck and/or Sophora flavescens and/or Hibiscus rosa sin or Artemisia and/or Rheum and/or Schisandra and/or Ophio ensis and/or Phyllanthus emblica (syn. Emblica officinalis) pogon japonicus. and/or Centella asiatica and/or Ganoderma and/or Rubia [0033] In yet another embodiment, the composition of the cordifolia and/or Scutellaria baicalensis and/or Ocimum present invention comprises Acorus and one or more agents tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or selected from the group consisting of Albizia lebbeck and/or Artemisia and/or Rheum and/or Schisandra and/or Ophio Sophora flavescens and/or Hibiscus rosa sinensis and/or pogon japonicus. Phyllanthus emblica (syn. Emblica officinalis) and/or Aza [0027] In yet another embodiment, the composition of the dirachta indica and/or Centella asiatica and/or Ganoderma present invention comprises Centella asiatica and one or and/or Rubia cordifolia and/or Scutellaria baicalensis and/or more agents selected from the group consisting of Albizia Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Artemi lebbeck and/or Sophora flavescens and/or Hibicus rosa sin sia and/or Rheum and/or Schisandra and/or Ophiopogon ensis and/or Phyllanthus emblica (syn. Emblica officinalis) japonicus. and/or Azadirachta indica and/or Ganoderma and/or Rubia [0034] In yet another embodiment, the composition of the cordifolia and/or Scutellaria baicalensis and/or Ocimum present invention comprises Artemisia and one or more tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or agents selected from the group consisting of Albizia lebbeck Artemisia and/or Rheum and/or Schisandra and/or Ophio and/or Sophora flavescens and/or Hibiscus rosa sinensis and/ pogon japonicus. or Phyllanthus emblica (syn. Emblica officinalis) and/or Aza [0028] In yet another embodiment, the composition of the dirachta indica and/or Centella asiatica and/or Ganoderma present invention comprises Ganoderma and one or more and/or Rubia cordifolia and/or Scutellaria baicalensis and/or agents selected from the group consisting of Albizia lebbeck Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or Sophora flavescens and/or Hibiscus rosa sinensis and/ and/or Rheum and/or Schisandra and/or Ophiopogon japoni or Phyllanthus emblica (syn. Emblica officinalis) and/or Aza Cº?.S. dirachta indica and/or Centella asiatica and/or Rubia cordi [0035) In yet another embodiment, the composition of the folia and/or Scutellaria baicalensis and/or Ocimum present invention comprises Rheum and one or more agents tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or selected from the group consisting of Albizia lebbeck and/or Artemisia and/or Rheum and/or Schisandra and/or Ophio Sophora flavescens and/or Hibiscus rosa sinensis and/or pogon japonicus. Phyllanthus emblica (syn. Emblica officinalis) and/or Aza [0029] In yet another embodiment, the composition of the dirachta indica and/or Centella asiatica and/or Ganoderma present invention comprises Rubia cordifolia and one or more and/or Rubia cordifolia and/or Scutellaria baicalensis and/or agents selected from the group consisting of Albizia lebbeck Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or Sophora flavescens and/or Hibiscus rosa sinensis and/ and/or Artemisia and/or Schisandra and/or Ophiopogon or Phyllanthus emblica (syn. Emblica officinalis) and/or Aza japonicus. dirachta indica and/or Centella asiatica and/or Ganoderma [0036) In yet another embodiment, the composition of the and/or Scutellaria baicalensis and/or Ocimum tenuiflorum present invention comprises Schisandra and one or more (syn. Ocimum sanctum) and/or Acorus and/or Artemisia and/ agents selected from the group consisting of Albizia lebbeck or Rheum and/or Schisandra and/or Ophiopogon japonicus. and/or Sophora flavescens and/or Hibiscus rosa sinensis and/ [0030] In yet another embodiment, the composition of the or Phyllanthus emblica (syn. Emblica officinalis) and/or Aza present invention comprises Scutellaria baicalensis and one dirachta indica and/or Centella asiatica and/or Ganoderma or more agents selected from the group consisting of Albizia and/or Rubia cordifolia and/or Scutellaria baicalensis and/or lebbeck and/or Sophora flavescens and/or Hibiscus rosa sin Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus ensis and/or Phyllanthus emblica (syn. Emblica officinalis) and/or Artemisia and/or Rheum and/or Ophiopogon japoni and/or Azadirachta indica and/or Centella asiatica and/or Cº?.S. Ganoderma and/or Rubia cordifolia and/or Ocimum tenuiflo [0037] In yet another embodiment, the composition of the rum (syn. Ocimum sanctum) and/or Acorus and/or Artemisia present invention comprises Ophiopogon japonicus and one and/or Rheum and/or Schisandra and/or Ophiopogon japoni or more agents selected from the group consisting of Albizia Cº?.S. lebbeck and/or Sophora flavescens and/or Hibiscus rosa sin [0031] In yet another embodiment, the composition of the ensis and/or Phyllanthus emblica (syn. Emblica officinalis) present invention comprises Astragalus membranaceus and and/or Azadirachta indica and/or Centella asiatica and/or one or more agents selected from the group consisting of Ganoderma and/or Rubia cordifolia and/or Scutellaria US 2015/0297652 A1 Oct. 22, 2015

baicalensis and/or Ocimum tenuiflorum (syn. Ocimum sanc anti-inflammatory agents (e.g. corticosteroids or calcineurin tum) and/or Acorus and/or Artemisia and/or Rheum and/or inhibitors), hormones (e.g. androgens, estrogens), apigenin Schisandra. as well as additional herbal ingredients such as Eclipta pros [0038] In one embodiment, a composition of the present trata (syn. Eclipta alba), Carthamus tinctorius, invention is formulated for topical administration to a cuta [0044] Schisandra nigra, Polygonum multiflorum (syn. neous or mucosal surface. Fallopia multiflora), Trigonella foenum-graecum, Sapindus [0039] In another embodiment, a composition of the mukorossi, Thuja occidentalis, Herpestis Monniera, Bacopa present invention is formulated for intralesional administra monnieri, Acacia concinna, and other relevant ingredients tion to a cutaneous or mucosal surface. listed herein. [0040] In yet another embodiment, a composition of the present invention is formulated for oral administration to a Antioxidant/Anti-Aging mucousal surface. [0041) Examples of topical, intralesional and oral formula [0045] For formulations of the present invention for use as tions include, but are not limited to, ointments, creams, antioxidants in disorders of photodamage and photoaging, in lotions, solutions, pastes (e.g. facial mask), gels, emulsions, addition to Albizia lebbeck and/or Sophora flavescens and/or sprays, aerosols, oils, patches, toothpastes, mouthwashes, Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. deodorants, soaps, body and/or face washes, sponges, foams, Emblica officinalis) and/or Azadirachta indica and/or Cen semi-solids, cosmetics (e.g. solid, semisolid, liquid, or pow tella asiatica and/or Ganoderma and/or Rubia cordifolia and/ der foundation, eye shadow, lip balm), application sticks, or Scutellaria baicalensis and/or Astragalus membranaceus sunscreens, depots, suppositories, sustained-release formula and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or tions (a unique variation of this concept presented herein Acorus and/or Artemisia and/or Rheum and/or Schisandra involves tea bag-like carriers made of plastic, silk, nylon, and/or Ophiopogon japonicus, the formulation of the present Soilon or paper), troches, tablets, pills, capsules, syrups, elix invention may further comprise, for example, one or more of irs, suspensions, wafers, foods (e.g. chewing gum, mints, established antioxidant oranti-aging therapies which include, etc.), beverages or other formulations which accomplishes but are not limited to retinol, retinoids and derivatives thereof direct contact between the composition of the present inven (e.g. adapalene, tretinoin, isotretinoin, acitretin, tazarotene), tion and a cutaneous or mucosal surface or lesion. hydroquinone, and active sunscreen ingredients (e.g. ami [0042] The compositions of the present invention are useful nobenzoic acid, avobenzone, anthranilates, cinnamates, octi in preventing, treating, alleviating symptoms and/or mitigat noxate, cinoxate, benzophenones, dioxybenzone, Oxyben ing skin disorders and/or diseases. Examples of such skin zone, Homosalate, Octocrylene, Octyl methoxycinnamate, disorders and/or diseases include, but are not limited to, neo Octisalate, Mexoryl SX, PABA derivatives, benzoic acid, plasms, infections, disorders of inflammation, proliferation, Padimate O, Phenylbenzimidazole sulfonic acid, Sulisoben autoimmunity, hypersensitivity, pruritus, photodamage or zone, Titanium dioxide, Trolamine salicylate, Zinc oxide). Examples of antioxidants include, but are not limited to ascor photoaging, wound healing, angiogenesis, hair, nails, odor or byl palmitate, ascorbic acid (vitamin C), tetrahexyldecyl hyperhidrosis, and pigmentation. In one embodiment, a com ascorbate, vitamin A, vitamin E acetate, ferulic acid, alpha position of the present invention is applied topically to pre lipoic acid, especially DL-alpha-lipoic acid, biotin, folic acid, vent, treat, alleviate symptoms and/or mitigate the skin dis coenzyme Q10, glutathione, tripeptides and peptides, lipo order and/or disease. In another embodiment, a composition chroman-6, magnesium ascorbyl phosphate, (–)-epigallocat of the present invention is applied intralesionally to treat echin-3-gallate, catechins, galangin, rutin, luteolin, morin, alleviate symptoms and/or mitigate the skin disorder and/or fisetin, silymarin, Coenzyme Q10, apigenin, gingkolides, disease. In another embodiment, a composition of the present hesperidin, citrin, caffeine and caffeine salts, niacinamide, invention is administered orally to treat alleviate symptoms nicotinamide, xanthines, anthocyanins (e.g. pelargonidin and/or mitigate the skin disorder and/or disease. In these 3-glucoside, cyanidin 3-glucoside, delphinidin 3-glucoside, embodiments, the topical, intralesional or oral formulation of pelargonidin 3,5-diglucoside, cyanidin 3,5-diglucoside and the present invention may further comprise one or more addi delphinidin 3,5-diglucoside), ellagitannins, hydrolysable tional pharmaceutical ingredients established for use in a skin tannins (e.g. punicalin, pedunculagin, punicalagin, gallagic disorder or disease. and ellagic acid esters of glucose), and derivatives thereof which exhibit antioxidant activity. Antioxidant enzymes are Hair Disorders further contemplated for use in the compositions of the [0043] For formulations of the present invention for use in present invention, such as superoxide dismutase, catalase, hair disorders, in addition to Albizia lebbeck and/or Sophora glutathione peroxidase, methionine reductase, and equiva flavescens and/or Hibiscus rosa sinensis and/or Phyllanthus lents thereof. These antioxidant enzymes can prevent the emblica (syn. Emblica officinalis) and/or Azadirachta indica formation of free radicals or scavenge the formed free radi and/or Centella asiatica and/or Ganoderma and/or Rubia cals to prevent cell damage. Flavonoids and/or flavonoid cordifolia and/or Scutellaria baicalensis and/or Astragalus derivatives are also contemplated for inclusion in composi membranaceus and/or Ocimum tenuiflorum (syn. Ocimum tions of the present invention. Examples of flavonoids and/or sanctum) and/or Acorus and/or Artemisia and/or Rheum and/ flavonoid derivatives and/or include, but are not or Schisandra and/or Ophiopogon japonicus, the formulation limited to quercetin, quercetrin, myricetin, kaempferol, of the present invention may further comprise, for example, myrecetrin and genistein as these compounds also have some one or more established hair growth effectors such as, but not anti-inflammatory activity and/or can help stabilize cell limited to, minoxidil, efornithiquinone, prostaglandin ago membranes in combination with relatively low toxicity. Also, nists or antagonists (e.g. brimatoprost and latanoprost), 5-al pharmaceutically acceptable salts of these flavonoids and/or pha reductase inhibitors (e.g. finasteride, dutasteride) and flavonoid derivatives may be employed. The particular fla otheranti-androgenic agents (e.g. spironolactone, flutamide), vonoid and/or flavonoid derivative included in the composi US 2015/0297652 A1 Oct. 22, 2015

tion can be determined by factors such as toxicity, bioavail mycin), anti-fungal agents (e.g. ketoconazole, nystatin, ability, solubility or dispersability, among others. Additional econazole, terbinafine, griseofulvin, ciclopirox, miconazole, herbal ingredients which can be included in formulations of thymol, zeasorb, nafitine, amphotericin), antivirals (e.g. acy the present invention for use as antioxidants in disorders of clovir, docosanol, penciclovir, valacyclovir, cidofovir, foscar photodamage and photoaging include, but are not limited to net, imiquimod, canthacur, squaric acid), scabicides (e.g. per Glycyrrhiza glabra, Pterocarpus santalinus, Vitis vinifera, methrin, ivermectin, lindane, malathion), pediculicides, anti Punica granatum, Polygonum multiflorum (syn. Fallopia helmintic (e.g. benzimidazoles, diethylcarbamazine, multiflora), Soy, Olea europaea, Cinnamomum cassia, ivermectin, pyrantel pamoate, levamisole), residuimod, ben Momordica charantia, Phoenix Dactylyfera, Poria cocos, zoyl peroxide, silvadene, pentavalent antimony (e.g. stibo Syzygium cumini, Trigonella foenum-graecum, Terminalia gluconate), salicyclic acid, sulfur, sulfacetamide, pyrithione chebula, Cucurbitapepo, Moringa oleifera, Tinospora cordi zinc, selenium sulfide, vinegar, and other relevant ingredients folia, Cajanus cajan, Kinobeon A, Santalum album, Rubia listed herein. Additional herbal ingredients which can be cordifolia, Lonicera caerulea, Vaccinium myrtillus, Hibiscus included in formulations of the present invention for use as sabdariffa, Iris Florentina Root, Arbutin, Pyrus, Oenothera antimicrobial agents include, but are not limited to Hemides biennis, Aframomum angustifolium, Plumbago zeylanica, mus indicus, Melaleuca alternifolia, Hydrastis canadensis, Polypodium leucotomos, Hemidesmus indicus, Terminalia Mahonia aquifolium, Andrographis paniculata, Manuka bellerica, Caesalpinia crista, Nardostachys jatamansi, Salix honey (e.g. methylglyoxal), Agastache rugosa, Dichroa feb nigra, Rosmarinus officinalis (e.g. Oleoresin), rifuga, Tridax procumbens, Lobelia chinensis, Ocimum basi Camellia sinensis, Hamamelis virginiana, Mangifera indica, licum, Melia azedarach, Aloysia triphylla, Acacia concinna, biloba, Cocos nucifera (e.g. Coconut endosperm), Rhus javanica, Picea abies (syn. Norway spruce), and San Piper nigrum (e.g. tetrahydropiperine), Terminalia arjuna, talum album. Terminalia muelleri, Thuja standishii, Crocus sativus, Sesa mum indicum, (genera Elettaria and Amomum), Anti-Neoplastic Ligusticum wallichii (Tetramethylpyrazine), Phellodendron amurense, Pueraria lobata, Eucommia ulmoides, Ocimum [0047] For formulations of the present invention for use as basilicum, Bacopa monniera, Aloysia triphylla, Prunella vul anti-neoplastic agents, in addition to Albizia lebbeck and/or garis, Arctium lappa, Angelica dahurica, Forsythia suspense, Sophora flavescens and/or Hibiscus rosa sinensis and/or Salvia miltiorrhiza, Mesua ferrea, Malabathrum, Cucumis Phyllanthus emblica (syn. Emblica officinalis) and/or Aza satius, Broussonetia papyrifera, Morus bombycis and Tan dirachta indica and/or Centella asiatica and/or Ganoderma acetum parthenium. Additional active agents which can be and/or Rubia cordifolia and/or Scutellaria baicalensis and/or included in formulations of the present invention for use as Astragalus membranaceus and/or Ocimum tenuiflorum (syn. antioxidants or in anti-aging include, but are not limited to, Ocimum sanctum) and/or Acorus and/or Artemisia and/or lycopene, resveratrol, C-carotene, [3-carotene, L-ergothion Rheum and/or Schisandra and/or Ophiopogon japonicus, the eine, kojic acid, N-acetylglucosamine, hyaluronic acid, formulation of the present invention may further comprise, alpha-hydroxy acids (e.g. glycolic acid, lactic acid, citric for example, one or more of established anti-neoplastic thera acid), beta-hydroxy acids (e.g salicylic acid), trichloroacetic pies which include, but are not limited to cytotoxic agents acid, bisabolol (syn. levomenol), amber extract, colnibin, such as TAXOL, Cytochalasin B, Gramicidin D, Ethidium L-Carnitine, exfoliants (e.g. aluminum oxide crystals), kine Bromide, Emetime, Mitomycin, Etoposide, Tenoposide, Vin tin, statins, peptides (e.g. argireline and copper peptides), cristine, Vinblastine, resorcinol, solid carbon dioxide slush, phenol, Isolagen, bro [0048] Colchicin, Doxorubicin, Daunorubicin, Mitox melain and other relevant ingredients listed herein. In one antrone, Mithramycin, Actinomycin D, 1–Dehydrotestoster embodiment, the composition is administered topically, one, Glucocorticoids, Procaine, Tetracaine, Lidocaine, and intralesionally or orally before, after or simultaneously with Puromycin and analogs or homologs thereof. Therapeutic photodynamic therapy, dermabrasion, ablative and non-abla agents include, but are not limited to, antimetabolites (e.g., tive lasers (e.g. pulsed dye laser, Erb:YAG, CO2, Nd:YAG, Methotrexate, 6-Mercaptopurine, 6-Thioguanine, Cytara Fraxel, Q-switched, Diode, Argon, Pulse excimer, Krypton, bine, 5-Fluorouracil, Decarbazine), alkylating agents (e.g., Copper, V-beam), intense pulsed light (syn. IPL), plasmaki Mechlorethamine, Thiotepa, Chlorambucil, Melphalan, Car netic rejuvenation, photo-pneumatic technology, electro-op mustine (BCNU), Lomustine (CCNU), Cyclophosphamide, tical synergy, or electrosurgery. Busulfan, Dibromomannitol, Streptozotocin, Mitomycin C, Cis-Dichlorodiamine Platinum (II) (DDP), Cisplatin), anthracyclines (e.g., Daunorubicin (formerly Daunomycin) Antimicrobial and Doxorubicin), antibiotics (e.g., Dactinomycin (formerly [0046] For formulations of the present invention for use as Actinomycin), Bleomycin, Mithramycin, and Anthramycin antimicrobial agents, in addition to Albizia lebbeck and/or (AMC)), anti-mitotic agents (e.g., Vincristine and Vinblas Sophora flavescens and/or Hibiscus rosa sinensis and/or time) and new agents such as Selective Apoptotic Antine Phyllanthus emblica (syn. Emblica officinalis) and/or Aza oplastic Drugs (SAANDs) such as APTOSYNR (Exisulind). dirachta indica and/or Centella asiatica and/or Ganoderma Additional active agents which can be included in formula and/or Rubia cordifolia and/or Scutellaria baicalensis and/or tions of the present invention for use in the treatment of Astragalus membranaceus and/or Ocimum tenuiflorum (syn. neoplastic conditions include, but are not limited to imiqui Ocimum sanctum) and/or Acorus and/or Artemisia and/or mod, diclofenac (e.g. Solaraze), interferon, ipilimumab, Rheum and/or Schisandra and/or Ophiopogon japonicus, the BRAF-inhibitors (e.g. venurafenib), MEK-inhibitors, PD-1 formulation of the present invention may further comprise, inhibitors, nitrogen mustard, bexarotene, timolol or pro for example, one or more of established antimicrobial thera panolol, corticosteroids, ingenol mebutate, rapamycin, siroli pies which include, but are not limited to antibiotics (e.g. mus, imatinib, oxymetazoline hydrochloride, aminolevulinic clindamycin, metronidazole, mupirocin, polysporin, genta acid (syn. Levulan), methyl aminolevulinic acid (syn. MET US 2015/0297652 A1 Oct. 22, 2015

VIX), hedgehog pathway inhibitors (e.g. vismodegib, syn. ran), anakinra (syn. Kineret), omalizumab (syn. Xolair), Erivedge"M), resiguimod, and other relevant ingredients cyclosporine (syn. Neoral), cyclophosphamide (syn. listed herein. Additional herbal ingredients which can be Cytoxan), mycophenolate mofetil (syn. Cellcept or Myfor included in formulations of the present invention for use as tic), thalidomide, rituximab, ustekinumab (syn. Stelara), ale antimicrobial agents include, but are not limited to Punica facept, leflunomide, methoxypsoralen (syn. oxsoralen), granatum, Terminalia Arjuna, Tinospora cordifolia, Rubia immunoglobulins, sulfasalazine, mesalamine, bromelain, cordifolia, Gelsemium sempervirens, Thuja standishii, Aegle brodalumab and other immunomodulators and immunosup marmelos, Scutellaria barbata, Phellodendron amurense, pressants and other relevant ingredients listed herein. Addi Momordica charantia, Angelica dahurica, and Perilla frute tional herbal ingredients which can be included in formula scens. As will be understood by the skilled artisan upon tions of the present invention for use as anti-proliferative reading this disclosure, many of the agents listed above are agents include, but are not limited to Punica granatum, Ter more effective when administered systemically. Accordingly, minalia arjuna, Tinospora cordifolia, Rubia cordifolia, and an aspect of the present invention also relates to use of a Malabathrum. In one embodiment, the composition of the composition of the present invention topically, intralesionally present invention is administered before, after or simulta or orally in combination with systemic administration of an neously with ultraviolet B radiation, ultraviolet A radiation, established antineoplastic treatment for the treatment of a photodynamic therapy, dermabrasion, ablative and non-abla neoplastic skin disorder to disease. Compositions of the tive lasers (e.g. pulsed dye laser, Erb:YAG, CO2, Nd:YAG, present invention can be administered alone or in combina Fraxel, Q-switched, Diode, Argon, Pulse excimer, Krypton, tion with agents established to relieve effects of cancer and/or Copper), intense pulsed light (syn. IPL), electrosurgery, side effects of cancer before, simultaneously with, or follow administration of a chemical peeling agent (e.g. trichloroace ing, the administration of a composition of the present inven tic acid, glycolic acid, salicyclic acid, recorcinol, lactic acid, tion. Examples of agents which relieve side effects of cancer phenol, croton oil) or sclerosing agents (e.g. hypertonic include, but are not limited to, Epoetin alfa to relieve symp saline, sodium tetradecyl sulfate, SOTRADECOLTM, poli toms of anemia; cell protecting agents such as amifostine; and docanol, sodium morrhuate, ethanolamine oleate, glycerin, Strontium-89 and Samarium-153 for the relief of cancer polyiodine iodine), plasmakinetic rejuvenation, photo-pneu induced bone pain; and oral antibiotics (e.g. minocycline), matic technology, electro-optical synergy, electrosurgery, corticosteroids, keratolytics, and retinoids for the relief of and/or administration of a vasoconstrictor (e.g. catechola drug induced acneiform and papulosquamous eruptions. mines, oxymetazoline, phenylephrine, caffeine, theophyl line, epinephrine, ergot compounds, triptans), penicillamine, Anti-Proliferative tetracycline, cytokine (e.g. IL-12), matrix metalloproteinase inhibitor (e.g. batimastat and marimastat), direct angiogen [0049] For formulations of the present invention for use as esis inhibitor (e.g. bevacizumab, vascular endothelial growth anti-proliferative agents, in addition to Albizia lebbeck and/or factor receptor antagonists, angiostatin, basic fibroblast Sophora flavescens and/or Hibiscus rosa sinensis and/or growth factor), or indirect angiogenesis inhibitor (e.g. Ras Phyllanthus emblica (syn. Emblica officinalis) and/or Aza dirachta indica and/or Centella asiatica and/or Ganoderma signaling inhibitors, farnesyltranferase inhibitors). and/or Rubia cordifolia and/or Scutellaria baicalensis and/or Disorders of Pigmentation Astragalus membranaceus and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or Artemisia and/or [0050] For formulations of the present invention for use in Rheum and/or Schisandra and/or Ophiopogon japonicus, the disorders of pigmentation, in addition to Albizia lebbeck and/ formulation of the present invention may further comprise, or Sophora flavescens and/or Hibiscus rosa sinensis and/or for example, one or more of established anti-neoplastic thera Phyllanthus emblica (syn. Emblica officinalis) and/or Aza pies which include, but are not limited to retinol or retinoids dirachta indica and/or Centella asiatica and/or Ganoderma and derivatives thereof (e.g., isotretinoin, acitretin, ada and/or Rubia cordifolia and/or Scutellaria baicalensis and/or palene, tretinoin, tazorac), vitamin D analogs (e.g. calcitriol, Astragalus membranaceus and/or Ocimum tenuiflorum (syn. calcipotriene), calcineurin inhibitors (e.g. tacrolimus, pime Ocimum sanctum) and/or Acorus and/or Artemisia and/or crolimus), corticosteroids (e.g. clobetasol, betamethasone, Rheum and/or Schisandra and/or Ophiopogon japonicus, the triamcinolone, hydrocortisone, prednisone), keratolytics formulation of the present invention may further comprise, (e.g. urea, azelaic acid, salicylic acid, lactic acid, and other for example, one or more of established pigmentation thera alpha- or beta-hydroxyacids), nicotinamide, gentian violet, pies which include, but are not limited to kojic acid, lignin Vincristine or vinblastine, liquor carbonis detergens, nitrogen peroxidase, belides, soy extracts, niacinamide, N-acetylglu mustard, bexarotene, alpha- or beta-agonists or antagonists cosamine, aloesin, bleaching agents (e.g. hydroquinone, (e.g. timolol or propranolol), calcium channel blockers, benoquin), benzoyl peroxide, retinol or retinoids and deriva 5-fluorouracil, imiquimod, sinecatechins (e.g. Veregen), can tives thereof (e.g., isotretinoin, acitretin, adapalene, tretinoin, thacur, squaric acid, podofilox, podophyllin, benzoin, ingenol tazorac), active sunscreen ingredients (e.g. aminobenzoic mebutate, rapamycin, bleomycin, intralesional candida anti acid, avobenzone, anthranilates, cinnamates, octinoxate, gen, cidofovir, imatinib, oxymetazoline hydrochloride, ami cinoxate, benzophenones, dioxybenzone, Oxybenzone, molevulinic acid (syn. Levulan), hedgehogpathway inhibitors Homosalate, Octocrylene, Octyl methoxycinnamate, Octis (e.g. vismodegib, syn. Erivedge"), emollients (e.g. ceram alate, Mexoryl SX, PABA derivatives, benzoic acid, Padimate ides), coal tar, targel, tarshampoo, antibiotics (e.g., doxycy O, Phenylbenzimidazole sulfonic acid, Sulisobenzone, Tita cline, metronidazole, trimethoprim-sulfamethaxole, cephal nium dioxide, Trolamine salicylate, Zinc oxide), alpha-Arbu exin), anthralin, anti-tumor-necrosis-factor inhibitors (e.g. tin (syn. 4-Hydroxyphenyl-O-D-glucopyranoside), cal adalimumab, etanercept, infliximab), methotrexate, diamino cineurin inhibitors (e.g. tacrolimus, pimecrolimus), diphenyl sulfone (syn. dapsone), hydroxychloroquine (syn. corticosteroids (e.g. clobetasol, betamethasone, triamcino plaquenil), chloroquine, quinacrine, azathioprine (syn. Imu lone, hydrocortisone, prednisone), keratolytics (e.g. urea, US 2015/0297652 A1 Oct. 22, 2015

azelaic acid, salicylic acid, lactic acid, and other alpha- or oxsoralen), immunoglobulins, sulfasalazine, mesalamine, beta-hydroxyacids), nicotinamide, bromelain, caffeine and bromelain, brodalumab and other immunomodulators and derivatives thereof. Additional herbal ingredients which can immunosuppressants. Additional herbal ingredients which be included informulations of the present invention for use in can be included in formulations of the present invention for pigmentation disorders include, but are not limited to Glycyr use as anti-inflammatory agents include, but are not limited rhiza glabra, Morus alba, Syzygium aromaticum, Punica to, Terminalia chebula (e.g. chebulagic acid), Embelia ribes, granatum, Arbutin, Cinnamomum cassia, Citrus aurantium, Vitex negundo, Picrorhiza kurroa, Pterocarpus santalinus, Oenothera biennis, Trigonella foenum-graecum, Withania Punica granatum, Terminalia arjuna, Tinospora cordifolia, somnifera, Atractylodes, Platycodon graniflorus, Angelica Rubia cordifolia, Eclipta alba (syn. eclipta prostrata), Ros dahurica, Cucumis Satius, Broussonetia kazinoki, Brous marinus officinalis, Boswellia serrate, Citrus aurantium, Cin sonetia papyrifera, Perilla frutescens, Cornus officinalis, namomum cassia, Trigonella foenum-graecum, Pyrus, Rhus javanica, Morus bombycis, Quercus dentate, Lonicera caerulea, Vaccinium myrtillus, Diosgenin, Cocos Schizopepon bryoniaefolius, Pinus densiflora, and Capsella nucifera, Mahonia aquifolium, Andrographis paniculata, bursa-pastoris. In one embodiment, the composition is Aegle marmelos, Fritillaria thunbergii, Calendula, Crocus administered topically, intralesionally or orally before, after sativus, Coptis, Cardamom (Genera Elettaria and Amomum), or simultaneously with ultraviolet B radiation, ultraviolet A Dichroa febrifuga, Leonurus japonicus, Ligusticum wallichii radiation, photodynamic therapy, dermabrasion, ablative and (e.g. tetramethylpyrazine), Lobelia chinensis, Phellodendron non-ablative lasers (e.g. pulsed dye laser, Erb:YAG, CO2, amurense, Rehmannia glutinosa, Eucommia ulmoides, Nd:YAG, Fraxel, Q-switched, Diode, Argon, Pulse excimer, Gleditsia sinensis, Trichosanthes, Melia azedarach, Astraga Krypton, Copper), intense pulsed light (syn. IPL), electrosur lus membranaceus, Platycodon graniflorus, Arctium lappa, gery, chemical peeling agents (e.g. trichloroacetic acid, gly Forsythia suspense, Salvia miltiorrhiza, Leonurus sibiricus, colic acid, salicyclic acid, recorcinol, lactic acid, phenol, Mesua ferrea, Malabathrum, Bacopa monnieri, Broussonetia croton oil), and other relevant ingredients listed herein. kazinoki, Perilla frutescens, Morus bombycis, Camellia sin ensis, Glycyrrhiza glabra and . In one Anti-Inflammatory embodiment, the composition is administered topically, [0051] For formulations of the present invention for use as intralesionally or orally before, after or simultaneously with anti-inflammatory agents, in addition to Albizia lebbeck and/ ultraviolet B radiation, ultraviolet A radiation, photodynamic or Sophora flavescens and/or Hibiscus rosa sinensis and/or therapy, dermabrasion, ablative and non-ablative lasers (e.g. Phyllanthus emblica (syn. Emblica officinalis) and/or Aza pulsed dye laser, Erb:YAG, CO2, Nd:YAG, Fraxel, dirachta indica and/or Centella asiatica and/or Ganoderma Q-switched, Diode, Argon, Pulse excimer, Krypton, Copper, and/or Rubia cordifolia and/or Scutellaria baicalensis and/or V-beam), intense pulsed light (syn. IPL), electrosurgery, and Astragalus membranaceus and/or Ocimum tenuiflorum (syn. other relevant ingredients listed herein. Ocimum sanctum) and/or Acorus and/or Artemisia and/or Rheum and/or Schisandra and/or Ophiopogon japonicus, the Wound Healing formulation of the present invention may further comprise, for example, one or more of established anti-inflammatory [0052] For formulations of the present invention for use as therapies which include, but are not limited to pycnogenol, wound healing agents, in addition to Albizia lebbeck and/or oatmeal, avenanthramides, bisabolol (syn. Levomenol), D Sophora flavescens and/or Hibiscus rosa sinensis and/or and L-Panthenol, azelaic acid, non-steroidal anti-inflamma Phyllanthus emblica (syn. Emblica officinalis) and/or Aza tory drugs (e.g. aspirin, ibuprofen, piroxicam), statins, dirachta indica and/or Centella asiatica and/or Ganoderma chlorambucil, acetaminophen, allopurinol, hydroxyurea, and/or Rubia cordifolia and/or Scutellaria baicalensis and/or penicillamine, cromolyn sodium, colchicine, diclofenac, ret Astragalus membranaceus and/or Ocimum tenuiflorum (syn. inol or retinoids and derivatives thereof (e.g., isotretinoin, Ocimum sanctum) and/or Acorus and/or Artemisia and/or acitretin, adapalene, tretinoin, tazorac), vitamin D analogs Rheum and/or Schisandra and/or Ophiopogon japonicus, the (e.g. calcitriol, calcipotriene), calcineurin inhibitors (e.g. tac formulation of the present invention may further comprise, rolimus, pimecrolimus), corticosteroids (e.g. clobetasol, for example, one or more of established wound healing thera betamethasone, triamcinolone, hydrocortisone, prednisone), pies which include, but are not limited to hydrocolloids (e.g. keratolytics (e.g. urea, azelaic acid, salicylic acid, lactic acid, Duoderm), silvadene, alginates (e.g. Sorbsan), hydrogels and otheralpha-orbeta-hydroxyacids), liquor carbonis deter (e.g. Vigilon), foam dressing (e.g. Flexzan, Allevyn and Vigi gens, nicotinamide, gentian violet, vincristine or vinblastine, foam), hydrofibers (e.g. carboxymethyl cellulose), non-ad nitrogen mustard, bexarotene, rapamycin, bleomycin, cido herent fabrics (e.g. gauze, telfa pad, xeroform, hydrophobic, fovir, imatinib, oxymetazoline hydrochloride, hedgehog hydrophilic), occlusive or moisture retentive dressings (e.g. pathway inhibitors (e.g. vismodegib,syn. Erivedge"M), emol nonbiologic, foam, film, biologic, antimicrobial, cadexomer lients (e.g. ceramides), coaltar, targel, tarshampoo, rifampin, iodine, silver dressing), corticosteroids (e.g. clobetasol, antibiotics (e.g., doxycycline, metronidazole, trimethoprim betamethasone, triamcinolone, hydrocortisone, prednisone), sulfamethaxole, cephalexin), anthralin, anti-tumor-necrosis keratolytics (e.g. urea, salicylic acid, lactic acid, and other factor inhibitors (e.g. adalimumab, etanercept, infliximab), alpha- or beta-hydroxyacids), antiseptic agents including but methotrexate, diaminodiphenyl sulfone (syn. dapsone), not limited to alcohol, chlorhexidine (e.g. Hibiclens), iodine, hydroxychloroquine (syn. plaquenil), chloroquine, quina iodophors (e.g. betadine), technicare PCMX chloroxylenol, crine, azathioprine (syn. Imuran), anakinra (syn. Kineret), triclosan, benzalkonium (quaternary ammonium), septisol, omalizumab (syn. Xolair), cyclosporine (syn. Neoral), cyclo bromelain, antibiotics (e.g. clindamycin, metronidazole, phosphamide (syn. Cytoxan), mycophenolate mofetil (syn. mupirocin, gentamycin, erythromycin and retapamulin), Cellcept, Myfortic), thalidomide, rituximab, ustekinumab anti-fungal agents (e.g. ketoconazole, nystatin, econazole, (syn. Stelara), alefacept, leflunomide, methoxypsoralen (syn. terbinafine, amphotericin, butenafine, naftifine and thymol), US 2015/0297652 A1 Oct. 22, 2015 antivirals (e.g. acyclovir, valacyclovir, cidofovir, foscarnet, Disorders of Odor and Hyperhidrosis imiquimod, cantharidin and squaric acid), scabicides (e.g. [0055] For formulations of the present invention for use in [0053] permethrin), pediculicides, anti-helminthics (e.g. disorders of odor and hyperhidrosis, in addition to Albizia benzoyl peroxide), silvadene, pentavalent antimony (e.g. sti lebbeck and/or Sophora flavescens and/or Hibiscus rosa sin bogluconate), salicyclic acid, sulfur, sulfacetamide, anti-dan ensis and/or Phyllanthus emblica (syn. Emblica officinalis) druff agents (e.g. pyrithione zinc, selenium sulfide, alkyl iso and/or Azadirachta indica and/or Centella asiatica and/or quinolinium bromide, allantoin, benzalkonium chloride), Ganoderma and/or Rubia cordifolia and/or Scutellaria vinegar, collagen and derivates thereof (e.g. human, bovine, baicalensis and/or Astragalus membranaceus and/or Oci porcine, synthetic collagen), Autologen, dermalogen, fas mum tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/ cian, isolagen, hyaluronic acid, silicone, liquid bandages (e.g. or Artemisia and/or Rheum and/or Schisandra and/or Ophio SkinStitchTM), Pentoxifylline (syn. Trental), analgesics (e.g. pogon japonicus, the formulation of the present invention may further comprise, for example, one or more of estab lidocaine, prilocaine, pramoxine), acetic acid, aluminum lished therapies which include, but are not limited to, acetate (e.g. Burow’s solution), sodium hypochlorite Cetylpyridinium chloride, menthol, thymol, methyl salicy (Dakin’s solution), stanozolol and danazol, peptides (e.g. late, eucalyptol, aluminum chloride (syn. Drysol), and gly argireline and copperpeptides), vitamins, antioxidants, emol copyrrolate (syn. Robinul), botulinum toxin, anticholinergics lients, calming agents, anti-pruritics, and other relevantingre (e.g. atropine), calcineurin inhibitors (e.g. tacrolimus, pime dients listed herein. Additional herbal ingredients which can crolimus), corticosteroids (e.g. clobetasol, betamethasone, be included informulations of the present invention for use as triamcinolone, hydrocortisone, prednisone), keratolytics antimicrobial agents include, but are not limited to Hemides (e.g. urea, azelaic acid, salicylic acid, lactic acid, and other mus indicus, Melaleuca alternifolia, Punica granatum, alpha- or beta-hydroxyacids), retinol or retinoids and deriva Momordica charantia, Terminalia chebula, Rosmarinus offi tives thereof (e.g., isotretinoin, acitretin, adapalene, tretinoin, cinalis, Tephrosia purpurea, Terminalia arjuna, Yashada tazorac), vitamin D analogs (e.g. calcitriol, calcipotriene), bhasma, Shorea robusta resin, seed oil, Calendula, Cro nicotinamide, gentian violet, liquor carbonis detergens, nitro cus sativus, Symphytum officinale, Tridax procumbens, Tri gen mustard, bexarotene, alpha- or beta-agonists or antago chosanthes, Bacopa monniera, Arctium lappa, Angelica nists (e.g. timolol or propranolol), oxymetazoline hydrochlo dahurica, Picea abies (syn. Norway spruce), and Bacopa ride, aminolevulinic acid (syn. Levulan), emollients (e.g. monnieri. ceramides), coal tar, targel, tar shampoo, antibiotics (e.g. clindamycin, metronidazole, mupirocin, polysporin, genta Anti-Pruritics/Emollients/Xerosis mycin), anti-fungal agents(e.g. ketoconazole, nystatin, econazole, terbinafine, griseofulvin, ciclopirox, miconazole, [0054] For formulations of the present invention for use as thymol, zeasorb, nafitine, amphotericin), antivirals (e.g. acy anti-pruritics, emmollients and/or in xerosis, in addition to clovir, docosanol, penciclovir, valacyclovir, cidofovir, foscar Albizia lebbeck and/or Sophora flavescens and/or Hibiscus net, imiquimod, canthacur, squaric acid), scabicides (e.g. per rosa sinensis and/or Phyllanthus emblica (syn. Emblica offi methrin, ivermectin, lindane, malathion), pediculicides, anti cinalis) and/or Azadirachta indica and/or Centella asiatica helmintic (e.g. Benzimidazoles, Diethylcarbamazine, and/or Ganoderma and/or Rubia cordifolia and/or Scutel Ivermectin, Pyrantel pamoate, Levamisole), residuimod, laria baicalensis and/or Astragalus membranaceus and/or benzoyl peroxide, silvadene, pentavalent antimony (e.g. sti Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus bogluconate), salicyclic acid, sulfur, sulfacetamide, and/or Artemisia and/or Rheum and/or Schisandra and/or pyrithione zinc, selenium sulfide, vinegar, anthralin, anti Ophiopogon japonicus, the formulation of the present inven tumor-necrosis-factor inhibitors (e.g. adalimumab, etaner tion may further comprise, for example, one or more of estab cept, infliximab), methotrexate, diaminodiphenyl sulfone lished therapies which include, but are not limited to Cocos (syn. dapsone), hydroxychloroquine (syn. plaquenil), chloro nucifera (coconut oil), Sesamum indicum, Cucumis Satius, quine, quinacrine, azathioprine (syn. Imuran), anakinra (syn. root extracts (e.g. , gingko), dexpenthanol, silymarin, Kineret), omalizumab (syn. Xolair), cyclosporine (syn. lipids, sterols, omega-3 fatty acids, ceramides, , Neoral), cyclophosphamide (syn. Cytoxan), Mycophenolate , calamine, camphor, menthol, eucalyptus, pep mofetil (syn. Cellcept, Myfortic), thalidomide, rituximab, permint, capsaicin, antihistamines (e.g. diphenahydramine, ustekinumab (syn. Stelara), alefacept, leflunomide, Methox hydroxyzine, cyproheptadine, loratidine, desloratadine, fex ypsoralen (syn. oxsoralen), immunoglobulins, sulfasalazine, ofenadine, cetirizine), H2-blockers (e.g. famotidine, cimeti mesalamine, brodalumab and other immunomodulators and dine, ranitidine), pramoxine, doxepin, promethazine hydro immunosuppressants, and other relevant ingredients listed chloride, antidepressants (e.g. amitriptyline, TCA’s, SSRI’s, herein. Additional herbal ingredients which can be included venlafaxine), antipsychotics (e.g. pimozide), maltrexone, informulations of the present invention for use in disorders of ondansetron, cholestyramine, estrogen and estradiol and odors and hyperhidrosis include, but are not limited to Andro derivatives thereof, rifampin, coal tar, targel, tar shampoo, pogon jwarankus, Mesua ferrea, Terminalia chebula, vitamins and minerals (e.g. calcipotriene, calcitriol, zinc, Hemidesmus indicus, Melaleuca alternifolia, Hydrastis etc), opioids, anesthetics and analgesics (e.g. lidocaine, Canadensis, Mahonia aquifolium, Andrographis paniculata, prilocaine, benzocaine, bupivicane, tetracaine, procaine, Manuka honey (e.g. Methylglyoxal), Agastache rugosa, morphine, fentanyl), calcineurin inhibitors (e.g. tacrolimus, Dichroa febrifuga, Tridax procumbens, Lobelia chinensis, pimecrolimus), corticosteroids (e.g. clobetasol, betametha Ocimum basilicum, Melia azedarach, Aloysia triphylla, Aca sone, triamcinolone, hydrocortisone, prednisone), keratolyt cia concinna, Rhus javanica, Picea abies (syn. Norway ics (e.g. urea, azelaic acid, salicylic acid, lactic acid, and other spruce), and Santalum album. In one embodiment, the com alpha- or beta-hydroxyacids), and other relevant ingredients position is administered topically or intralesionally before, listed herein. after or simultaneously with dermabrasion, ablative and non US 2015/0297652 A1 Oct. 22, 2015

ablative lasers (e.g. pulsed dye laser, Erb:YAG, CO2, febrifuga, Leonurus japonicus, Ligusticum wallichii (tetram Nd:YAG, Fraxel, Q-switched, Diode, Argon, Pulse excimer, ethylpyrazine), Lobelia chinensis, Phellodendron amurense, Krypton, Copper), photodynamic therapy, intense pulsed Rehmannia glutinosa, Eucommia ulmoides, Gleditsia sinen light (syn. IPL), electrosurgery, chemical peeling agents (e.g. sis, Trichosanthes, Melia azedarach, Astragalus membrana trichloroacetic acid, glycolic acid, salicyclic acid, recorcinol, ceus, Platycodon graniflorus Arctium lappa, Forsythia sus lactic acid, phenol, croton oil) and other relevant ingredients pense, Salvia miltiorrhiza Leonurus sibiricus, Mesua ferrea, listed herein. Malabathrum, Bacopa monnieri, Broussonetia kazinoki, Perilla frutescens, Morus bombycis, Camellia sinensis, Gly Disorders of Hypersensitivity and Autoimmunity cyrrhiza glabra and Tanacetum parthenium. In one embodi ment, the composition is administered topically or intrale [0056] For formulations of the present invention for use in sionally before, after or simultaneously with ultraviolet B disorders of hypersensitivity and autoimmunity, in addition to radiation, ultraviolet A radiation, photodynamic therapy, Albizia lebbeck and/or Sophora flavescens and/or Hibiscus dermabrasion, ablative and non-ablative lasers (e.g. pulsed rosa sinensis and/or Phyllanthus emblica (syn. Emblica offi dye laser, Erb:YAG, CO2, Nd:YAG, Fraxel, Q-switched, cinalis) and/or Azadirachta indica and/or Centella asiatica Diode, Argon, Pulse excimer, Krypton, Copper, V-beam), and/or Ganoderma and/or Rubia cordifolia and/or Scutel intense pulsed light (syn. IPL), electrosurgery, and other rel laria baicalensis and/or Astragalus membranaceus and/or evant ingredients listed herein. Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/or Artemisia and/or Rheum and/or Schisandra and/or Disorders of Angiogenesis Ophiopogon japonicus, the formulation of the present inven tion may further comprise, for example, one or more of estab [0057] For formulations of the present invention for use in lished therapies which include, but are not limited to, Pycno angiogenic disorders, in addition to Albizia lebbeck and/or genol, oatmeal, avenanthramides, bisabolol (syn. Sophora flavescens and/or Hibiscus rosa sinensis and/or Levomenol), D- and L-Panthenol, azelaic acid, non-steroidal Phyllanthus emblica (syn. Emblica officinalis) and/or Aza anti-inflammatory drugs (e.g. aspirin, ibuprofen, piroxicam), dirachta indica and/or Centella asiatica and/or Ganoderma statins, chlorambucil, acetaminophen, allopurinol, hydrox and/or Rubia cordifolia and/or Scutellaria baicalensis and/or yurea, penicillamine, cromolyn sodium, colchicine, Astragalus membranaceus and/or Ocimum tenuiflorum (syn. diclofenac, retinol or retinoids and derivatives thereof (e.g., Ocimum sanctum) and/or Acorus and/or Artemisia and/or isotretinoin, acitretin, adapalene, tretinoin, tazorac), vitamin Rheum and/or Schisandra and/or Ophiopogon japonicus, the D analogs (e.g. calcitriol, calcipotriene), calcineurin inhibi formulation of the present invention may further comprise, tors (e.g. tacrolimus, pimecrolimus), corticosteroids (e.g. clo for example, one or more of established angiogenic therapies betasol, betamethasone, triamcinolone, hydrocortisone, which include, but are not limited to vasoconstrictors (e.g. prednisone), keratolytics (e.g. urea, azelaic acid, salicylic catecholamines, oxymetazoline, phenylephrine, caffeine, acid, lactic acid, and other alpha- or beta- hydroxyacids), theophylline, epinephrine, ergot compounds, triptans), peni liquor carbonis detergens, nicotinamide, gentian violet, vin cillamine, tetracyclines, cytokines (e.g. IL-12), Matrix met cristine or vinblastine, nitrogen mustard, bexarotene, rapa alloproteinase inhibitors (e.g. batimastat and marimastat), mycin, bleomycin, cidofovir, imatinib, oxymetazoline hydro direct angiogenesis inhibitors (e.g. bevacizumab, vascular chloride, hedgehog pathway inhibitors (e.g. vismodegib,syn. endothelial growth factor receptor antagonists, angiostatin, Erivedge", emollients (e.g. ceramides), coal tar, targel, tar basic fibroblast growth factor), indirect angiogenesis inhibi shampoo, rifampin, antibiotics (e.g., doxycycline, metronida tors (e.g. Ras-signaling inhibitors, farnesyltranferase inhibi zole, trimethoprim-sulfamethaxole, cephalexin), anthralin, tors), sclerosing agents (e.g. hypertonic saline, sodium tet anti-tumor-necrosis-factor inhibitors (e.g. adalimumab, etan radecyl sulfate, SOTRADECOLTM, polidocanol, sodium ercept, infliximab), methotrexate, diaminodiphenyl sulfone morrhuate, ethanolamine oleate, glycerin, polyiodine (syn. dapsone), hydroxychloroquine (syn. plaquenil), chloro iodine), and other relevant ingredients listed herein. Addi quine, quinacrine, azathioprine (syn. Imuran), anakinra (syn. tional herbal ingredients which can be included in formula Kineret), omalizumab (syn. Xolair), cyclosporine (syn. tions of the present invention for use in angiogenic disorders Neoral), cyclophosphamide (syn. Cytoxan), Mycophenolate include, but are not limited to, Scutellaria barbata, Lobelia mofetil (syn. Cellcept, Myfortic), thalidomide, rituximab, chinensis, Gleditsia sinensis and Melia zedarach. ustekinumab (syn. Stelara), alefacept, leflunomide, methox [0058] Topical, intralesional and oral formulations for use ypsoralen (syn. oxsoralen), immunoglobulins, sulfasalazine, in the present invention can be prepared by methods and mesalamine, brodalumab and other immunomodulators and contain carriers which are well-known in the art. A generally immunosuppressants. Additional herbal ingredients which recognized compendium of such methods and ingredients is can be included in formulations of the present invention for Remington: The Science and Practice of Pharmacy, Alfonso use in disorders of hypersensitivity and autoimmunity R. Gennaro, editor, 20th ed. Lippingcott Williams & Wilkins: include, but are not limited to, Fritillaria thunbergii, Rehman Philadelphia, Pa., 2000. nia glutinosa, Terminalia chebula, Embelia ribes, Vitex [0059] Formulations suitable for application to a cutaneous negundo, Picrorhiza kurroa, Pterocarpus santalinus, Punica or mucosal surface topically, intralesionally or orally can take granatum, Terminalia arjuna, Tinospora cordifolia, Rubia the form of an ointment, cream, lotion, solution, paste (e.g. cordifolia, Eclipta alba (syn. eclipta prostrata), Rosmarinus [0060) facial mask), gel, emulsion, spray, aerosol, oil, officinalis, Boswellia serrate, Citrus aurantium, Cinnamo patch, toothpaste, mouthwash, deodorant, soap, body and/or mum cassia, Trigonella foenum-graecum, Pyrus, Lonicera face wash, sponge, foam, semi-solid, cosmetic (e.g. solid, caerulea, Vaccinium myrtillus, Diosgenin, Cocos nucifera, semisolid, liquid, or powder foundation, eye shadow, lip Mahonia aquifolium, Andrographis paniculata, Aegle balm), application stick, sunscreen, depot, suppository, sus marmelos, Fritillaria thunbergii, Calendula, Crocus sativus, tained-release formulation (a unique variation of this concept Coptis, Cardamom (genera Elettaria and Amomum), Dichroa presented herein involves tea bag-like carriers made of plas US 2015/0297652 A1 Oct. 22, 2015 tic, silk, nylon, Soilon or paper), troche, tablet, pill, capsule, vasoconstrictors (e.g. caffeine, oxymetazoline hydrochlo syrup, elixir, suspension, wafer, food (e.g. chewing gum, ride, theophylline), agents that inhibit angiogenesis, pain mints, etc.), beverage or other formulation which accom relievers oranesthetics (e.g. lidocaine, benzocaine), as well as plishes direct contact between the composition of the present other suitable materials that do not have a significant adverse invention and a cutaneous or mucosal surface or lesion. For effect on the activity of the topical composition. Additional mulations can also be prepared which are suitable for collu ingredients can include, for example a sodium acid phosphate sive therapy. moisturizer, witch hazel extract, glycerine humectant, apricot [0061| Such formulations should contain at least 0.1% of kernel oil emollient, corn oil dispersant, ceramides, or inosi Albizia lebbeck and/or Sophora flavescens and/or Hibiscus tol. rosa sinensis and/or Phyllanthus emblica (syn. Emblica offi [0064] For oral therapeutic administration, a composition cinalis) and/or Azadirachta indica and/or Centella asiatica of the present invention can be combined with one or more and/or Ganoderma and/or Rubia cordifolia and/or Scutel carriers and used in the form of for example, ingestible laria baicalensis and/or Astragalus membranaceus and/or tablets, buccal tablets, troches, capsules, elixirs, suspensions, Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus syrups, wafers, chewing gums, mints, foods, beverages and and/or Artemisia and/or Rheum and/or Schisandra and/or the like. Ophiopogon japonicus. The percentage of the ingredient or [0065] In addition to Albizia lebbeck and/or Sophora flave ingredients and preparations can, of course, be varied and can scens and/or Hibiscus rosa sinensis and/or Phyllanthus conveniently be between about 0.1 to about 100% of the emblica (syn. Emblica officinalis) and/or Azadirachta indica weight of a given unit dosage form. The amount of each and/or Centella asiatica and/or Ganoderma and/or Rubia ingredient in such compositions is such that an effective dos cordifolia and/or Scutellaria baicalensis and/or Astragalus age level will be obtained. membranaceus and/or Ocimum tenuiflorum (syn. Ocimum [0062] Formulations in the forms of ointments, creams, sanctum) and/or Acorus and/or Artemisia and/or Rheum and/ lotions and pastes can generally have carriers in the forms of or Schisandra and/or Ophiopogon japonicas, tablets, troches, oleaginous bases (e.g., White Petrolatum and White Oint pills, capsules, foods and energy drinks and the like can also ment); absorption bases formed by adding a water-in-oil contain the following: binders such as gum tragacanth, aca emulsifying agent to an oleaginous base (e.g., Hydrophilic cia, corn starch, or gelatin; excipients such as dicalcium phos Petrolatum, AQUABASE, and AQUAPHOR), water-in-oil phate; a disintegrating agent such as corn starch, potato emulsion bases, prepared by adding water to an absorption starch, alginic acid and the like; a lubricant such as magne base (e.g., HYDROCREAM, EUCERIN, NIVEA, and Cold sium Stearate; and a Sweetening agent such as sucrose, fruc Cream); oil-in-water emulsion bases (e.g., DERMABASE, tose, lactose, sucralose, or aspartame or a flavoring agent such UNIBASE, VELVACHOL, and hydrophilic ointment); water as , oil of wintergreen, or cherry flavoring. The soluble bases (e.g., polyethylene glycol ointment such as abovelisting is merely representative and one skilled in the art PEG 400-600 G or PEG 3350-400 G); and any other com could envision other binders, excipients, sweetening agents, mercially available compounding base. Suitable carriers to flavoring agents, coloring agents, and fragrances, and the like. produce a spray, gel, solution, aerosol, emulsions, foam, When the unit dosage form is a capsule, it can contain, in semisolids, soap, wash, shampoo, deodorant, makeup foun addition to materials of the above type, a liquid carrier, such dation, lip balms, mouthwash, or toothpaste are well-known as a vegetable oil or a polyethylene glycol. Various other in the art. materials can be present as coatings or to otherwise modify [0063) A carrier for topical or intralesional application can the physical form of the solid unit dosage form. For instance, also contain additional ingredients such as other carriers, tablets, pills, or capsules can be coated with gelatin, wax, moisturizers, humectants, emollients, dispersants, radiation shellac or sugar and the like. blocking compounds (chemical orphysical blockers), cleans [0066] Suspensions, syrups or elixirs can contain Albizia ing agents, wetting agents, emulsifiers, lubricants (e.g. lebbeck and/or Sophora flavescens and/or Hibiscus rosa sin sodium lauryl sulfate and magnesium stearate), as well as ensis and/or Phyllanthus emblica (syn. Emblica officinalis) coloring agents, release agents, coating agents, sweetening, and/or Azadirachta indica and/or Centella asiatica and/or flavoring, and perfuming agents, preservatives, flavonoids, Ganoderma and/or Rubia cordifolia and/or Scutellaria and antioxidants, anti-microbial agents (e.g. antibiotics, fun baicalensis and/or Astragalus membranaceus and/or Oci gicides, scabicides, pediculicides, benzoyl peroxide, salicy mum tenuiflorum (syn. Ocimum sanctum) and/or Acorus and/ clic acid, sulfur, sulfacetamide, pyrithione zinc), anti-inflam or Artemisia and/or Rheum and/or Schisandra and/or Ophio matory agents (e.g. corticosteroids, calcineurin inhibitors), pogon japonicus as well as sweetening agents (e.g. Sucrose or keratolytics (agents that soften, loosen, and facilitate exfolia fructose, preservative (e.g. methyl and propylparabens), dyes tion of the squamous cells of the epidermis; e.g. urea or and flavoring agents (e.g. cherry or orange flavor), sterile ammonium lactate), anti-photoaging (e.g. retinol or retin diluents (e.g. water, saline, oils), buffers (e.g. acetates, cit oids), anti-pigmentation agents (e.g. hydroquinone), anti-per rates, orphosphates), chelating agents (e.g. ethylenediamine spirants (e.g. aluminum chloride, aluminum zirconium), anti tetraacetic acid), agents for the adjustment of tonicity (e.g. neoplastic agents (e.g. imiquimod, 5-fluorauracil), anti dextrose, sodium chloride). Of course, any material used in pruritics, or cooling and calming agents (e.g. calamine, preparing any unit dosage form should be substantially non camphor, menthol, capsaicin, antihistamines, coal tar), vita toxic in the amounts employed. In addition, Albizia lebbeck mins and minerals (e.g. calcipotriene, calcitriol, zinc, etc), and/or Sophora flavescens and/or Hibiscus rosa sinensis and/ root extracts (e.g. ginger, gingko), antioxidants (e.g. caffeine or Phyllanthus emblica (syn. Emblica officinalis) and/or Aza and caffeine salts, apigenin), hair-growth effectors (e.g. dirachta indica and/or Centella asiatica and/or Ganoderma minoxidil, efornithine, prostaglandin analogs or antago and/or Rubia cordifolia and/or Scutellaria baicalensis and/or nists), flavoring agents, sweeteners, coloring agents, fra Astragalus membranaceus and/or Ocimum tenuiflorum (syn. grances, dental products (e.g. whitening agents, fluoride), Ocimum sanctum) and/or Acorus and/or Artemisia and/or US 2015/0297652 A1 Oct. 22, 2015

Rheum and/or Schisandra and/or Ophiopogon japonicus can quaternary ammonium salts), amphoteric surfactants (e.g., be incorporated into sustained-release preparations and lecithins, cephalins, alkylbetamines), nonionic surfactants devices including but not limited to, those relying on osmotic (mono-, di-, and triglycerides), and other fatty acids and alco pressure diffusion gradients to obtain a desired release pro hols (e.g., lauryl, cetyl, and stearyl alcohols), sucrose, sorbi file. tan and PEG, urea and N,N-dimethyl-m-toluamide. [0067] All the formulations presented in this patent for the [0071] Formulations suitable for transdermal administra Albizia lebbeck and/or Sophora flavescens and/or Hibiscus tion can be presented as discrete patches adapted to remain in rosa sinensis and/or Phyllanthus emblica (syn. Emblica offi intimate contact with the epidermis of the recipient for a cinalis) and/or Azadirachta indica and/or Centella asiatica prolonged period of time. There are different designs of the and/or Ganoderma and/or Rubia cordifolia and/or Scutel patch system that dictate release characteristics of the active laria baicalensis and/or Astragalus membranaceus and/or agent and patch behavior: (i) matrix or monolithic and (ii) Ocimum tenuiflorum (syn. Ocimum sanctum) and/or Acorus reservoir or membrane. In the matrix system, the inert poly and/or Artemisia and/or Rheum and/or Schisandra and/or mer matrix binds with the active agent and controls its release Ophiopogon japonicus may be prepared with carriers that from the device. In the reservoir system, the polymer matrix protect the agent against rapid release, such as controlled does not control release of the active agent. Instead, a rate release formulations, including implants, transdermal controlling membrane present between the drug matrix and patches, microencapsulated (e.g. silicone matrices) or nano the adhesive layer provides the rate-limiting barrier for particle delivery systems. Biodegradable, biocompatible release of the active agent from the device. It is contemplated polymers can be used, such as ethylene vinyl acetate, poly that either patch system is suitable for delivery of the com anhydrides, polyglycolic acid, collagen, polyorthoesters, positions disclosed herein. Formulations suitable for trans polylactic acid and polylactic, polyglycolic copolymers dermal administration can also be delivered by iontophoresis (PLG). Many methods for the preparation of such formula (see, for example, Pharmaceutical Research 3 (6):318 (1986)) tions are patented or generally known to those skilled in the and typically take the form of an optionally buffered aqueous art solution of the compound. Suitable formulations contain cit [0068] Alternatively, one can administer a composition rate or bis tris buffer (pH 6) or ethanol/water. containing Albizia lebbeck and/or Sophora flavescens and/or [0072] Compositions of the present invention are adminis Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. tered topically, intralesionally, or orally to the subject in an Emblica officinalis) and/or Azadirachta indica and/or Cen effective amount. tella asiatica and/or Ganoderma and/or Rubia cordifolia and/ [0073] By topical, intralesional and/or oral administration or Scutellaria baicalensis and/or Astragalus membranaceus it is meant to be inclusive of application to cutaneous as well and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or as mucosal surfaces. Acorus and/or Artemisia and/or Rheum and/or Schisandra [0074] By “effective amount” as defined herein, it is meant and/or Ophiopogon japonicas in a local manner, for example, an amount of a composition of the presentation wherein the in a depot, suppository, or sustained-release formulation. A levels of Albizia lebbeck and/or Sophora flavescens and/or unique variation of this concept presented herein involves tea Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. bag-like carriers made of plastic, silk, nylon, Soilon or paper. Emblica officinalis) and/or Azadirachta indica and/or Cen [0069| Nonlimiting examples of materials which can serve tella asiatica and/or Ganoderma and/or Rubia cordifolia and/ as carriers in formulations of compositions of the present or Scutellaria baicalensis and/or Astragalus membranaceus invention include sugars, such as lactose, glucose and and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or sucrose; starches, such as corn starch and potato starch; cel Acorus and/or Artemisia and/or Rheum and/or Schisandra lulose, and its derivatives, such as sodium carboxymethyl and/or Ophiopogon japonicus are adjusted such that the com cellulose, ethyl cellulose, and cellulose acetate; powdered position, when topically or intralesionally applied, prevents, tragacanth; malt; gelatin; talc, excipients, such as cocoa but treats, alleviates symptoms and/or mitigates a selected skin ter and suppository waxes; oils, such aspeanut oil, cottonseed disorder and/or disease. In embodiments of the present inven oil, safflower oil, sesame oil, olive oil, corn oil, coconut oil, tion comprising one or more additional pharmaceutical ingre and soybean oil; glycols, such as propylene glycol; polyols, dients established for use in a skin disorder or disease, the such as glycerin, sorbitol, mannitol, and polyethylene glycol; levels of Albizia lebbeck and/or Sophora flavescens and/or esters, such as magnesium hydroxide and aluminum hydrox Hibiscus rosa sinensis and/or Phyllanthus emblica (syn. ide; alginic acid; pyrogen-free water, isotonic saline; Ring Emblica officinalis) and/or Azadirachta indica and/or Cen er’s solution; ethyl alcohol; pH buffered solutions; polyes tella asiatica and/or Ganoderma and/or Rubia cordifolia and/ ters, polycarbonates and/or polyanhydrides; and other non or Scutellaria baicalensis and/or Astragalus membranaceus toxic compatible substances employed in formulations. and/or Ocimum tenuiflorum (syn. Ocimum sanctum) and/or [0070] In one embodiment, a topical formulation of the Acorus and/or Artemisia and/or Rheum and/or Schisandra present invention further contains transdermal or skin pen and/or Ophiopogon japonicus may be further adjusted so that etrant enhancers. Suitable skin penetrant enhancers include, the composition inclusive of the one or more additional ingre but are not limited to, solvents such as water, alcohols (e.g., dients, when topically, intralesionally, or orally administered methanol, ethanol, 2-propanol), alkyl methylsulfoxides (e.g., , prevents, treats, alleviates symptoms and/or mitigates a dimethylsulfoxide, decylmethyl sulfoxide, tetradecyl methyl selected skin disorder and/or disease. Thus, by “effective sulfoxide), pyrrolidones (e.g., 2-pyrrolidone, N-methyl-2 amount” of a composition of the present invention, it is meant pyrrolidone, N-(2-hydroxyethyl)pyrrolidone), laurocapram to include an amount sufficient to effect beneficial or desired (AZONE), and other solvents such as acetone, dimethyl results, including clinical results. As such, an effective acetamide, dimethyl formamide, tetrahydrofurfuryl alcohol; amount of the compositions is one which includes, but is not amphiphiles such as anionic surfactants (e.g., docusate limited to, alleviation or amelioration of one or more symp sodium, sodium lauryl sulfate), cationic surfactants (e.g., toms or conditions, diminishment of extent of disease, stabi US 2015/0297652 A1 Oct. 22, 2015 lized (i.e., not worsening) state of disease, preventing spread bug bites with complete resolution of itching, swelling, and of disease, delay or slowing of disease progression, amelio redness within 3 days. The treated areas resolved without ration or palliation of the disease state, and remission discoloration. The untreated areas were persistently pruritic, (whether partial or total), whether detectable or undetectable. became purpuric, and ultimately resolved with post inflam Treatment can also mean prolonging survival as compared to matory hyperpigmentation and discoloration after 3 weeks. expected survival if not receiving treatment. “Effective Subject 2 did not experience any adverse effects during or amount” is also meant to include levels which do not produce after treatment with Composition 1. unwanted side effects including, but not limited to, redness, [0081| Subject 3 suffered from chronic scalp dermatitis dryness, pain and/or pruritus. characterized by persistent severe itching and scaling of the [0075] Dosages for compositions of the present invention scalp. Subject 3 applied Composition 1 twice daily (every 12 can be determined by methods known in the art, see, e.g., hours) for 5 days to the scalp with significant reduction of Remington: The Science and Practice of Pharmacy, Alfonso itching and scaling of treated areas. Untreated areas were R. Gennaro, editor, 20th ed. Lippingcott Williams & Wilkins: persistently itchy and scaly. In the past, Subject 3 treated these Philadelphia, Pa., 2000 and can be administered for the pre areas on the scalp with clobetasol 0.05% solution, an ultrapo vention (i.e., before detectable signs or symptoms of a skin tent prescription topical steroid, the use of which was limited disorder or disease are observed) or treatment (i.e., after due to adverse side effects including acne and skin atrophy. detectable signs or symptoms of a skin disorder are observed) Subject 3 achieved similar results with application of Com of a skin disorder or disease. The selected effective dosage position 1 but without any adverse side effects. level will depend upon a variety of factors including the activity of the particular composition of the present invention [0082) Subject 4 suffered from stasis dermatitis character employed, whether the composition is used for prevention or ized by recurrent pruritic eczematous dermatitis of the lower treatment of the skin disorder or disease, the formulation legs due to chronic lower leg swelling and varicose veins. selected, the time of administration, the rate of excretion or Subject 4 applied Composition 1 to one leg and reported metabolism of the particular composition being employed, resolution of itching within 15 minutes of a single application the duration of the treatment, other drugs, compounds and/or and lasting for 5 days following treatment. Subject 4 reported materials used in combination with the particular composi persistent severe daily pruritus in the untreated leg. Subject 4 tion employed, the age, sex, weight, condition, general health did not experience any adverse effects with Composition 1. and prior medical history of the patient being treated, and like [0083) Subject 5 suffered from intermittent, episodic neu factors well-known in the medical arts. ropathic pruritus. Prior to treatment with Composition 1, [0076] A physician having ordinary skill in the art can Subject 5 had on average of 4-5 episodes of intense pruritus readily determine and prescribe the effective amount of the per day with each episode lasting up to 2 hours. Subject 5 composition of the present invention and the dosing regimen applied Composition 1 to affected areas and reported resolu required for prevention or treatment of the skin disorder in a tion of itching within 5-10 minutes of application. Subject 5 subject. By subject herein it meant to be inclusive of any also reported fewer episodes, 1-2 episodes per day, after 2 mammalian subject for which prevention or treatment of a days of using Composition 1. Subject 5 did not experience skin disorder or disease is sought. any adverse effects during treatment with Composition 1. [0077] The following nonlimiting examples further illus [0084]. Subject 6 suffered from arthropod hypersensitivity trate the instant claimed invention. characterized by purpuric and intensely pruritic urticarial plaques which typically resolve with post-inflammatory EXAMPLES hyperpigmentation and discoloration. Subject 6 applied Composition 1 only twice to affected areas with resolution of Example 1: Composition 1 itching. Subject 6 noted significant improvement of itching [0078] A topical composition of the present invention, within 10 minutes after each application. Untreated bug bites referred to herein as Composition 1, comprising as active persisted for 15 days with persistent itching, redness and ingredients Albizzia lebbeck (1%), schisandra chimensis ultimately resolved with post-inflammatory dark spots and (0.1%), and ophiopogon japonicus (2%), as well as petrola discoloration. Subject did not experience any adverse effects tum, water, glycerin, sodium hyaluronate, dimethicone, glyc with Composition 1. eryl Stearate, acrylates, disodium EDTA, capric triglyceride, [0085| Subject 7 suffered from pruritic eczematous patches propanediol, phenoxyethanol, and triethanolamine, was pre and xerosis on the lower legs due to lack of emollient use and pared and administered to subjects as follows: excessive washing with soap. Subject 7 applied Composition [0079| Subject 1 suffered from chronic eyelid eczema char 1 to one leg twice daily for 3 days with improvement of acterized by persistent severe itching and scaling of the eye dryness, scaling, and itching. Untreated areas on the legs and lids. Subject 1 previously treated the affected area with emol thigh continued to be persistently itchy and scaly despite lients and hydrocortisone with minimal improvement. emollient use. Subject 7 did not experience any adverse Subject 1 applied Composition 1 twice daily for 2 weeks with effects with composition 1. complete resolution of itching and scaling. Subject 1 sus tained remission at 2 months follow up. Subject 1 did not Example 2: Composition 2 experience any adverse effects during or after treatment with Composition 1. [0086] A topical composition of the present invention, [0080) Subject 2 suffered from arthropod hypersensitivity referred to herein as Composition 2, comprising as active characterized by large, purpuric, intensely pruritic urticarial ingredients Albizzia lebbeck (1%), phyllanthus emblica plaques which typically resolve with post-inflammatory (0.5%), azadirachta indica (2%), and centella asiatica hyperpigmentation and discoloration. Subject 2 applied (0.1%), as well as petrolatum, water, glycerin, sodium hyalu Composition 1 twice daily (every 12 hours) for 2 days to these ronate, dimethicone, glyceryl Stearate, acrylates, disodium US 2015/0297652 A1 Oct. 22, 2015

EDTA, capric triglyceride, propanediol, phenoxyethanol, and 2. A composition comprising Sophora flavescens and one triethanolamine, was prepared and administered to subjects or more agents selected from the group consisting of Albizia as follows: lebbeck, Hibiscus rosa sinensis, Phyllanthus emblica (syn. [0087| Subject 8 had a history of irritant contact dermatitis Emblica officinalis), Azadirachta indica, Centella asiatica, and sensitive skin. Subject 8 developed erythema, swelling, Ganoderma, Rubia cordifolia, Scutellaria baicalensis, and tenderness after threading of her eyebrows and upper lip Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci for hair removal. Subject 8 applied Composition 2 to the right mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and eyebrow immediately after threading and the right half of the Ophiopogon japonicus. uppercutaneous lip immediately after hair removal. Subject 8 3. A composition comprising Hibiscus rosa sinensis and had significant improvement of erythema, swelling, and ten one or more agents selected from the group consisting of derness within 8 minutes of applying Composition 2 as com Albizia lebbeck, Sophora flavescens, Phyllanthus emblica pared to up to 1 hour for the untreated areas. Subject 8 did not (syn. Emblica officinalis), Azadirachta indica, Centella asi experience any adverse effects with composition 2. atica, Ganoderma, Rubia cordifolia, Scutellaria baicalensis, [0088] Subject 9 applied Composition 2 to acne papules on Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci her face and had improvement,of pain and redness within 12 mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and hours of application. The treated papules did not evolve into Ophiopogon japonicus. pustules and completely resolved within 3-5 days without 4. A composition comprising Phyllanthus emblica (syn. post-inflammatory hyperpigmentation (dark spots). Many of Emblica officinalis) and one or more agents selected from the the untreated lesions on the face became pustular and group consisting of Albizia lebbeck, Sophora flavescens, resolved in 7-10 days with dark brown spots. The untreated Hibiscus rosa sinensis, Azadirachta indica, Centella asiatica, lesions remained painful and red for up to 7 days. Subject 9 Ganoderma, Rubia cordifolia, Scutellaria baicalensis, did not experience any adverse effects with application of Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci Composition 2. mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and Ophiopogon japonicus. Example 3: Composition 3 5. A composition comprising Azadirachta indica and one [0089] A topical composition of the present invention, or more agents selected from the group consisting of Albizia referred to herein as Composition 3, comprising as active lebbeck, Sophora flavescens, Hibiscus rosa sinensis, Phyllan ingredients Albizzia lebbeck (1%), astragalus membrana thus emblica (syn. Emblica officinalis), Centella asiatica, ceous (2%), ocimum sanctum (0.5%), and hibiscus rosa-sin Ganoderma, Rubia cordifolia, Scutellaria baicalensis, ensis (0.5%), as well as petrolatum, water, glycerin, sodium Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci hyaluronate, dimethicone, glyceryl Stearate, acrylates, diso mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and dium EDTA, capric triglyceride, propanediol, phenoxyetha Ophiopogon japonicus. nol, and triethanolamine, was prepared and administered to 6. A composition comprising Centella asiatica and one or subjects as follows: more agents selected from the group consisting of Albizia [0090] Subject 10 developed superficial erosions on his lebbeck, Sophora flavescens, Hibiscus rosa sinensis, Phyllan lower legs after indoor rock climbing. Subject 10 applied thus emblica (syn. Emblica officinalis), Azadirachta indica, Composition 3 twice daily for 3 contiguous days to a fresh Ganoderma, Rubia cordifolia, Scutellaria baicalensis, wound on the left lower leg. The treated lesion re-epithelial Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci ized within 12 hours of application compared to 24-36 hours mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and for untreated areas. At two weeks, the treated area resolved Ophiopogon japonicus. without post-inflammatory hyperpigmentation (darkening) 7. A composition comprising Ganoderma and one or more while untreated areas developed gray-brown discoloration. agents selected from the group consisting of Albizia lebbeck, Subject 10 did not experience burning or stinging or any other Sophora flavescens, Hibiscus rosa sinensis, Phyllanthus adverse effects with application of Composition 3. Neither emblica (syn. Emblica officinalis), Azadirachta indica, Cen site was infected during the study. tella asiatica, Rubia cordifolia, Scutellaria baicalensis, [0091]. Subject 11 developed traumatic cuts on the left Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci upper arm and left forearm from low lying shrubbery and mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and branches. Subject 11 is skin type 4 and typically develops Ophiopogon japonicus. dark brown scars with cuts. Subject 11 applied Composition 8. A composition comprising Rubia cordifolia and one or 3 immediately to the fresh wound on the left forearm, twice more agents selected from the group consisting of Albizia daily for 1 week. The treated area on the left forearm resolved lebbeck, Sophora flavescens, Hibiscus rosa sinensis, Phyllan in 1 week without forming a dark brown scar. The untreated thus emblica (syn. Emblica officinalis), Azadirachta indica, area on her left upper arm resolved 3 weeks after the injury Centella asiatica, Ganoderma, Scutellaria baicalensis, with a dark linear scar that was still present at 3 months follow Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci up. mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and What is claimed is: Ophiopogon japonicus. 1. A composition comprising Albizia lebbeck and one or 9. A composition comprising Scutellaria baicalensis and more agents selected from the group consisting of Sophora one or more agents selected from the group consisting of flavescens, Hibiscus rosa sinensis, Phyllanthus emblica (syn. Albizia lebbeck, Sophora flavescens, Hibiscus rosa sinensis, Emblica officinalis), Azadirachta indica, Centella asiatica, Phyllanthus emblica (syn. Emblica officinalis), Azadirachta Ganoderma, Rubia cordifolia, Scutellaria baicalensis, indica, Centella asiatica, Ganoderma, Rubia cordifolia, Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci Astragalus membranaceus, Ocimum tenuiflorum (syn. Oci mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and mum sanctum), Acorus, Artemisia, Rheum, Schisandra, and Ophiopogon japonicus. Ophiopogon japonicus. US 2015/0297652 A1 Oct. 22, 2015

10. A composition comprising Astragalus membranaceus 14. A composition comprising Rheum and one or more and one or more agents selected from the group consisting of agents selected from the group consisting of Albizia lebbeck, Albizia lebbeck, Sophora flavescens, Hibiscus rosa sinensis, Sophora flavescens, Hibiscus rosa sinensis, Phyllanthus Phyllanthus emblica (syn. Emblica officinalis), Azadirachta emblica (syn. Emblica officinalis), Azadirachta indica, Cen indica, Centella asiatica, Ganoderma, Rubia cordifolia, tella asiatica, Ganoderma, Rubia cordifolia, Scutellaria Scutellaria baicalensis, Ocimum tenuiflorum (syn. Ocimum baicalensis, Astragalus membranaceus, Ocimum tenuiflorum sanctum), Acorus, Artemisia, Rheum, Schisandra, and (syn. Ocimum sanctum), Acorus, Artemisia, Schisandra, and Ophiopogon japonicus. Ophiopogon japonicus. 11. A composition comprising Ocimum tenuiflorum (syn. 15. A composition comprising Schisandra and one or more Ocimum sanctum) and one or more agents selected from the agents selected from the group consisting of Albizia lebbeck, group consisting of Albizia lebbeck, Sophora flavescens, Sophora flavescens, Hibiscus rosa sinensis, Phyllanthus Hibiscus rosa sinensis, Phyllanthus emblica (syn. Emblica emblica (syn. Emblica officinalis), Azadirachta indica, Cen officinalis), Azadirachta indica, Centella asiatica, Gano tella asiatica, Ganoderma, Rubia cordifolia, Scutellaria derma, Rubia cordifolia, Scutellaria baicalensis, Astragalus baicalensis, Astragalus membranaceus, Ocimum tenuiflorum membranaceus, Acorus, Artemisia, Rheum, Schisandra, and (syn. Ocimum sanctum), Acorus, Artemisia, Rheum, and Ophiopogon japonicus. Ophiopogon japonicus. 12. A composition comprising Acorus and one or more 16. A composition comprising Ophiopogon japonicus and agents selected from the group consisting of Albizia lebbeck, one or more agents selected from the group consisting of Sophora flavescens, Hibiscus rosa sinensis, Phyllanthus Albizia lebbeck, Sophora flavescens, Hibiscus rosa sinensis, emblica (syn. Emblica officinalis), Azadirachta indica, Cen Phyllanthus emblica (syn. Emblica officinalis), Azadirachta tella asiatica, Ganoderma, Rubia cordifolia, Scutellaria indica, Centella asiatica, Ganoderma, Rubia cordifolia, baicalensis, Astragalus membranaceus, Ocimum tenuiflorum Scutellaria baicalensis, Astragalus membranaceus, Ocimum (syn. Ocimum sanctum), Artemisia, Rheum, Schisandra, and tenuiflorum (syn. Ocimum sanctum), Acorus, Artemisia, Ophiopogon japonicus. Rheum, and Schisandra. 13. A composition comprising Artemisia and one or more 17. . A topical, intralesional, or oral formulation compris agents selected from the group consisting of Albizia lebbeck, ing any of the compositions of claims 1-16 and a topically, Sophora flavescens, Hibiscus rosa sinensis, Phyllanthus intralesionally or orally acceptable carrier. emblica (syn. Emblica officinalis), Azadirachta indica, Cen 18. A method for treating oralleviating symptoms of a skin tella asiatica, Ganoderma, Rubia cordifolia, Scutellaria disease ordisorder, said method comprising topically, intrale baicalensis, Astragalus membranaceus, Ocimum tenuiflorum sionally, or orally administereing to a subject the formulation (syn. Ocimum sanctum), Acorus, Rheum, Schisandra, and of claim 17. Ophiopogon japonicus.